Targeted Chimeric Proteins for Ischemic Stroke Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic stroke and central nervous system disorders fail to effectively mitigate oxidative damage, repair the blood-brain barrier, reduce edema, and enhance neurologic and motor function recovery.
Innovation Solution
A chimeric protein comprising a variant of human insulin-like growth factor IGF-1, human serum albumin, and human Annexin 5 is administered to target and stimulate the phosphorylation of the AKT pathway, reducing oxidative damage and promoting tissue repair and functional recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ischemic stroke, then standard care is provided, but oxidative damage is not effectively mitigated and blood-brain barrier repair is insufficient
Solution Approach 1:
The patent applies composite materials by creating a chimeric protein that fuses three distinct functional domains: an IGF-1 variant activator domain, a human serum albumin half-life modulator domain, and an Annexin 5 targeting domain. This composite protein structure enables simultaneous multiple functions (targeting, activation, and prolonged circulation) that single proteins cannot achieve, directly resolving the contradiction by providing reliable treatment that effectively mitigates oxidative damage through targeted delivery of pro-survival signals to injured brain tissue.
2Reliability
If conventional treatments are used for ischemic stroke, then standard care is provided, but blood-brain barrier repair and edema reduction are insufficient
Solution Approach 1:
The chimeric protein acts as an intermediary that bridges the gap between systemic administration and localized brain tissue repair. The Annexin 5 targeting domain mediates specific binding to phosphatidylserine on injured brain cells, while the IGF-1 variant domain mediates activation of pro-survival signaling pathways. This intermediary protein simultaneously achieves blood-brain barrier repair and edema reduction through its targeted delivery mechanism, resolving the contradiction by providing reliable treatment that restores blood-brain barrier integrity.
3Reliability
If conventional treatments are used for ischemic stroke, then standard care is provided, but neurologic and motor function recovery is limited
Solution Approach 1:
The patent applies preliminary action by administering the chimeric protein within a critical time window (up to 72 hours) after stroke onset, before irreversible neuronal damage occurs. The IGF-1 variant domain preemptively activates pro-survival signaling pathways in vulnerable neurons, and the Annexin 5 targeting domain pre-positions the therapeutic at the injury site. This preliminary intervention significantly enhances neurologic and motor function recovery by protecting neurons before complete damage occurs, resolving the contradiction by providing reliable treatment that accelerates functional recovery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric protein effectively mitigates oxidative damage, repairs the blood-brain barrier, reduces infarct volume, and improves neurologic and motor function following ischemic stroke.
Implementation Method 1
The chimeric protein is selectively targeted to cells comprising a target molecule phosphatidylserine
Implementation Method 2
targeted stimulation of the phosphorylation of serine/threonine protein kinase B (AKT) pathway by selective activation of the IGF-1 receptor
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Aspects of the present disclosure relate generally to kits and methods for treating acute central nervous systems disorders with chimeric proteins and pharmaceutical compositions comprising such chimeric proteins.